Pei Hong, Linden Joel
Division of Developmental Immunology, La Jolla Institute for Allergy and Immunology, La Jolla, California.
Division of Developmental Immunology, La Jolla Institute for Allergy and Immunology, La Jolla, California
Am J Physiol Lung Cell Mol Physiol. 2016 May 15;310(10):L985-92. doi: 10.1152/ajplung.00330.2015. Epub 2016 Mar 25.
Agonists of adenosine A2A receptors (A2ARs) suppress the activation of most immune cells and reduce acute inflammatory responses. Asthma is characterized by sensitization in response to initial allergen exposure and by airway hyperreactivity in response to allergen rechallenge. We sought to determine if A2AR activation with CGS-21680 (CGS) is more effective when CGS is administered during sensitization or rechallenge. C57BL/6 wild-type mice and Adora2a(f/f)LysMCre(+/-) mice, which lack A2ARs on myeloid cells, were sensitized with intranasal ovalbumin (OVA) and LPS. Airway sensitization was characterized by a rapid increase in numbers of IL-6(+) and IL-12(+) macrophages and dendritic cells in lungs. A2AR activation with CGS (0.1 μg·kg(-1)·min(-1) sc) only during sensitization reduced numbers of IL-6(+) and IL-12(+) myeloid cells in the lungs and reversed the effects of OVA rechallenge to increase airway hyperresponsiveness to methacholine. CGS treatment during sensitization also reduced the expansion of lung T helper (Th1 and Th17) cells and increased expansion of regulatory T cells in response to OVA rechallenge. Most of the effects of CGS administered during sensitization were eliminated by myeloid-selective A2AR deletion. Administration of CGS only during OVA rechallenge failed to reduce airway hyperresponsiveness. We conclude that myeloid cells are key targets of adenosine during sensitization and indirectly modify T cell polarization. The results suggest that a clinically useful strategy might be to use A2AR agonists to inhibit sensitization to new aeroallergens. We speculate that adenosine production by macrophages engulfing bacteria contributes to the curious suppression of sensitization in response to early-life infections.
腺苷 A2A 受体(A2AR)激动剂可抑制大多数免疫细胞的激活并减轻急性炎症反应。哮喘的特征是对初次过敏原暴露产生致敏反应,以及对过敏原再次激发产生气道高反应性。我们试图确定在致敏或再次激发期间给予 CGS-21680(CGS)激活 A2AR 是否更有效。用鼻内卵清蛋白(OVA)和脂多糖对 C57BL/6 野生型小鼠和髓系细胞上缺乏 A2AR 的 Adora2a(f/f)LysMCre(+/-)小鼠进行致敏。气道致敏的特征是肺中 IL-6(+)和 IL-12(+)巨噬细胞及树突状细胞数量迅速增加。仅在致敏期间用 CGS(0.1 μg·kg(-1)·min(-1)皮下注射)激活 A2AR 可减少肺中 IL-6(+)和 IL-12(+)髓系细胞的数量,并逆转 OVA 再次激发增加气道对乙酰甲胆碱高反应性的作用。致敏期间的 CGS 治疗还减少了肺 T 辅助细胞(Th1 和 Th17)的扩增,并增加了对 OVA 再次激发的调节性 T 细胞扩增。髓系选择性 A2AR 缺失消除了致敏期间给予 CGS 的大部分作用。仅在 OVA 再次激发期间给予 CGS 未能降低气道高反应性。我们得出结论,髓系细胞是致敏期间腺苷的关键靶标,并间接改变 T 细胞极化。结果表明,一种临床上有用的策略可能是使用 A2AR 激动剂抑制对新的气传过敏原的致敏。我们推测,吞噬细菌的巨噬细胞产生的腺苷有助于对早期感染反应中致敏的奇特抑制。